CD226 and myasthenia gravis: Furthermore, pertaining to CD226 and TNFSF12, subgroup MR findings revealed a relationship between CD226 levels and late-onset MG (OR = 0.621; 95% CI 0.451–0.854; P = 3.412 × 10–3), as well as an association between TNFSF12 levels and late-onset MG (OR = 1.533; 95% CI 1.243–1.891; P = 6.570 × 10–5), while no statistically significant MR estimates were observed in the context of early-onset MG.